Developing a new antibiotic to fight drug-resistant bacteria
Official title: A new class of antibiotic to address Antimicrobial Resistance
Funded at Curza INC · NIH-11081814 · Data updated 2026-11-12
This study is working on new antibiotics to help fight tough bacteria that don't respond to regular treatments, aiming to create safe and effective options for people who need them.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Curza INC NIH-funded |
| Lab location | 1 site (Salt Lake City, UNITED STATES) |
| Project start | May 1, 2024 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $999,997 |
| NIH project number | 5R44AI184155-02 |
| Project ID | NIH-11081814 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with infections caused by multidrug-resistant Gram-negative bacteria.
✕Less likely to help
Patients with infections caused by non-resistant bacteria or those not infected may not benefit from this research.
What this research studies
This research focuses on creating a new class of antibiotics specifically designed to combat multidrug-resistant Gram-negative bacteria, such as Acinetobacter baumannii. The approach involves developing compounds that bind to a unique site on the bacterial ribosome, which is not targeted by existing antibiotics, thereby avoiding cross-resistance. By re-engineering a natural product, the researchers aim to produce antibiotics that are effective against these resistant pathogens while being safe for human cells. The project will advance a promising antibiotic candidate through critical testing stages.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients suffering from infections caused by antibiotic-resistant bacteria.
How similar studies have gone: Other research has shown promise in developing antibiotics targeting unique bacterial sites, indicating potential for success in this novel approach.
Where this research is happening
-
Curza INC
Salt Lake City, United States Active
Researchers
- Principal investigator: Testa, Charles — Curza INC
- Study coordinator: Testa, Charles
Related research
Other NIH-funded projects on the same topics.
-
New oral antibiotic for hard-to-treat Gram-negative infections
A program aims to create a new oral antibiotic that can fight multidrug-resistant Gram-negative bacteria.
-
Oral antibiotic for drug-resistant Gram-negative infections
An oral antibiotic being developed to treat people with serious multidrug-resistant Gram-negative bacterial infections.
-
A New Antibiotic for Tough-to-Treat Infections
This project is creating a new type of antibiotic called CZ-02 to fight serious infections caused by bacteria that resist many common medicines.
-
Developing new oral antibiotics to treat resistant bacterial infections
This study is working on a new type of antibiotic that can help treat tough infections caused by bacteria that don't respond to many current medicines, aiming to create a safe and effective pill for patients.
-
Developing new antibiotics to fight drug-resistant infections
This study is testing a new antibiotic called CZ-02 that aims to help people with tough infections, like urinary tract infections, caused by bacteria that are hard to treat because they resist current antibiotics.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.